Comprehensive Cancer Centers is constantly reviewing new options for clinical research. Please reference this page for news about new research efforts. If clinical research below is of interest, please select the research of interests, Email Us and we will send more information when it becomes available.

Pending Clinical Research Studies

This list contains pending trials data, and is subject to change.

i2738 TRIO-US/ Seattle Genetics       SGNTUC-016 III BREAST                               Ph 3 tucatinib or plac w/T-DMI loc adv or HER2+ BC Randomized. Double-blind. Phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
i2732 Roche/TRIO               CO41101 III BREAST                   Ipatasertib in Combo w/Atezo & Pac in mBC A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Of Ipatasertib In Combination With Atezolizumab And Paclitaxel As A Treatment For Patients With Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer
19122 Novartis           CBYL719H12301 III BREAST                         Ph 3 BYL719 + nabpax TNBC PIK3CA A phase III, three-part, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss but without PIK3CA mutation
Independent Sanofi             EFC15935 III BREAST                         Ph3 SAR439859 + Palbociclib vs Letrozole + Palbociclib A Randomized, Multicenter, Double-Blind Phase 3 Study Of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib For The Treatment Of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease
i2776 Hutchinson     Medi Pharma                     2019-013-GLOB1 III COLON                        Fresco-2 A Global, Multicenter, Randomized, Placebo Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colon Cancer (Fresco-2)
i2753 Oncologie, Inc.         ONCG100 II GASTRIC                         Ph2 Bav + Pembro in Gastric A Phase 2, Multicenter Open-Label, Non-Randomized Study of Bavituximab Plus Pembrolizumab In Patients With Advanced Gastric Or Gastroesophageal Cancer Who Have Progressed On Or After At Least One Prior Standard Therapy
Independent Daiichi Sankyo, Inc.             DS8201-A-U205 II GASTRIC                         Ph2 DS-8201A HER2+ in Gastric or GEJ A Phase 2, Open-Label, Single-Arm Trial Of Trastuzumab Deruxtecan (DS-8201A) In HER2-Positive, Unresectable Or Metastatic Gastric Or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed On Or After A Trastuzumab Containing Regimen
i2755 Amgen /TRIO                         510 20190009 III LUNG                           AMG 510 + Docetaxel in NSCLC w/ KRAS p.G12C Mutation A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510
Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with Mutated KRAS
i2772 Genentech             GO41836 II LUNG                           RO7198457 + Atezo vs Atezo in NSCLC A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum Doublet Chemotherapy In Patients Who Are CTDA Positive After Surgical Resection Of Stage II-III Non-Small Cell Lung Cancer
20137 Genentech             GO41854 III LUNG                           PH1/3 Atez Tira Dura Sg 3 NSCLC A Phase I/III, Randomized, Double-Blind,Placebo-Controlled Study Of Atezolizumab And Tiragolumab Compared With Durvalumab In Patients With Unresectable Stage Iii Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Independent ImmunityBio                 QUILT-2.023 II LUNG                           PH2 N-803 + Pembro vs Pembro in NSCLC A Phase 2, Open-Label, Randomized Study of N-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination with Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients with Advanced or Metastatic NSCLC
Independent AstraZeneca                 D5169C00001 III LUNG                           PH3 Osimertinib =/- Plat + Chemo in EGFR+ NSCLC A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
20176 Incyte                 INCMGA 002-204 II ENDOMETRIAL                       INCMGA00012 Endo Cancer An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Independent Salix Pharmaceuticals Inc.                           SAL-REL-2042 II/III PANCREAS                   Methylnaltrexone Bromide in aPancreatic A Phase II/III Adaptive Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects with Advanced Pancreatic Cancer
i2736 Laekna Limited     LAE201INT2101 II PROSTATE               LAE001/Pred + Afuresertib mCRPC A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
19236 GENENTECH                 WO41994 III RENAL                             PH3 Ate +Cabo Renal Carcinoma A Phase III, Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of Atezolizumab Given In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Inoperable, Locally Advanced, Or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During Or After Immune Checkpoint Inhibitor Treatment
Independent Astex             ASTX029-01 II SOLID TUMOR                                         ASTX209 in Solid Tumors A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
19040 Bayer                 BAY 88-8223/19781 II LUNG                             Ph 1/2 Rad-223+Pembro NSCLC An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer **PHASE 1B ENROLLMENT ON HOLD**
i2715 BioAtla LLC               BA3021-001 II SOLID TUMOR                             Ba3021 in Solid Tumors A Phase 1/2 Dose Escalation And Dose Expansion Study Of Ba3021 In Patients With Advanced Solid Tumors
Independent Genentech     BO41932 II SOLID TUMOR                             TAPISTRY Tumor-Agnostic Precision Immunooncology And Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
Independent IntralmmuSG           226688 II SOLID TUMOR                             PRL3-Zumab in Solid Tumors An Open Label, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors
Independent AstraZeneca                 D5339C00001 II SOLID TUMOR                             PLANETTE A Modular Phase 2a Multicentre Open-Label Study To Investigate DNA-Damage Response Agents (or Combinations) in Patients with Advanced Cancer Whose Tumours Contain Molecular Alteration (PLANETTE)
i2783 Merck                 V941-001-05 1 KRAS                             Ph 1 mRNA-5671/V941 + Pembro w/KRAS A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with
Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
i2759 Aravive                     AVB500-RCC-003 1 RENAL                             Ph 1 VB-S6-500 + Cabo in RCC A Phase lb/2 Randomized, Study Of A VB-S6-500 In Combination with Cabozantinib Versus Cabozantinib Alone in Patients with Advanced Clear Cell Renal Cell Carcinoma That Have Received Front-Line Treatment
Independent Zeno Alpha Inc.                     ZN-c5-001 1 BREAST                           Ph 1 ZN-C5 Combo in ER+ EGFR-02 aBC A Phase 1/2 Open Label, Multicenter Study To Assess The Safety, Tolerability, Pharmacokinetics, And Anti-Tumor Activity Of Zn-C5 Alone And In Combination With Palbociclib In Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
i2788 ESSA Pharma Inc.                               EPI-7386-CS-001 1 PROSTATE                           Ph 1 EPI-7386 in mCRPC A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer Protocol for Phase 1 Study of EPI-7386
i2780 Tolero Pharmaceticals                               TP-1454-101 1 SOLID TUMOR                           Ph 1 FIH TP-1454-101 +/- Combo of Ipi and Nivo A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab
Independent Merck Serono           MS200347-0046 1 CERVICAL                           Ph 1 Safety Study of Bintrafusp Combos in Cervical Cancer Safety Study of Bintrafusp alfa in Combination with Platinum + Paclitaxel ± Bevacizumab and Bintrafusp alfa in Combination with Platinum + Radiation Therapy in Participants with Advanced Cervical Cancer